Spotlight -

Drug Development|

Quality Systems

|Videos|May 27, 2023

Discussing Rapid Accurate mRNA Potency Assay Possibilities with Sean Hart

Author(s)Chris Spivey

Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.

Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on the topic of rapid accurate mRNA potency assay possibilities.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related Content

An Introduction to CPHI Milan 2026

ByTara Dougal,Susan Haigney

September 3rd 2026

Autonomous solubility tester. Imitation dissolution of the tablet in the human stomach. Scientific research of pharmaceutical laboratory. Laboratory research in pharmacy. | Image Credit: ©neznamov1984 -stock.adobe.com

Application of Predictive Modeling in the Development of Amorphous Solid Dispersions

ByCynthia A. Challener

September 3rd 2026

Novartis and Bristol-Myers Squibb pause CAR T-cell trials after 3 releated deaths.

CAR T-Cell Trial Pause Signals New Manufacturing Risk Review

ByZachary Zubulake

September 2nd 2026

Novartis makes a $3.2 Billion bet on a subcutaneous formulation platform.

What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation

ByZachary Zubulake

September 2nd 2026

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 2

ByRobert Holt, PhD,Susan Haigney

September 2nd 2026

Trending on Pharmaceutical Technology

What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation

CAR T-Cell Trial Pause Signals New Manufacturing Risk Review

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 1

AAPS PharmSci 360: CMC Strategies, Part 1

CPHI Milan Names 2026 Pharma Awards Finalists